Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oncotelic Therapeutics, Inc. (OTLC : OTC)

• Company Description    Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India. Number of Employees: 43

• Price / Volume Information    Yesterday's Closing Price: $0.06 Daily Weekly Monthly 20 Day Moving Average: 342,166 shares Shares Outstanding: 443.48 (millions) Market Capitalization: $25.72 (millions) Beta: -0.54 52 Week High: $0.11 52 Week Low: $0.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 58.47% 50.73% 12 Week 26.36% 16.81% Year To Date -26.02% -34.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 29397 AGOURA ROAD SUITE 107 - AGOURA HILLS,CA 91301 USA ph: 650-635-7000 fax: 650-635-7001 ir@oncotelic.com http://www.oncotelic.com

• General Corporate Information    Officers Vuong Trieu - President; Chief Executive Officer and Chairman Amit Shah - Chief Financial Officer Steven King - Director Anthony Maida - Director Steven W. King - Director and Consultant Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 628341109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 443.48 Most Recent Split Date: 12.00 (0.08:1) Beta: -0.54 Market Capitalization: $25.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 0.10 PEG Ratio: - Price Ratios Price/Book: 0.10 Price/Cash Flow: 0.10 Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - 183.45 12/31/25 - 350.62 09/30/25 - -22.16 ROA 03/31/26 - 117.54 12/31/25 - 210.10 09/30/25 - -6.17 Current Ratio 03/31/26 - 0.11 12/31/25 - 0.07 09/30/25 - 0.08 Quick Ratio 03/31/26 - 0.11 12/31/25 - 0.07 09/30/25 - 0.08 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.59 12/31/25 - 0.59 09/30/25 - 0.02 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.01 12/31/25 - 0.01 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.68 12/31/25 - 0.63 09/30/25 - 0.00

Powered by Zacks Investment Research ©